MHRA Tightens Safety Rules on Topiramate Amid Pregnancy Risk Fears
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) is cracking down on topiramate, known as Topamax, after a new European study revealed serious risks for unborn babies.
Topiramate Linked to Higher Risk of Autism and Intellectual Disabilities
The Commission on Human Medicines (CHM) reviewed fresh data showing children born to mums on topiramate face 2-3 times higher chances of intellectual disability, autism spectrum disorders, and ADHD. This alarming discovery has forced regulators to rethink how the drug is prescribed, especially during pregnancy.
Pregnancy Warning: Topiramate Restricted for Epilepsy and Migraines
- MHRA now advises doctors against prescribing topiramate for epilepsy in pregnant women unless no safer alternative exists.
- It should not be used at all for migraines during pregnancy due to its link with birth defects.
- Women of childbearing potential must use effective contraception and take a pregnancy test before starting treatment.
A special Pregnancy Prevention Programme includes a mandatory risk awareness form to ensure patients understand the dangers. Plus, certain birth control methods may not work well with topiramate, so consulting a GP or sexual health expert is crucial.
Over 30,000 Women Under 55 Use Topiramate Monthly in the UK
Topiramate is a common treatment for migraine and epilepsy, prescribed to more than 30,000 women monthly in England alone. Before this review, the drug was already known to increase risks of birth defects and low birth weight, but new measures aim to slash the number of topiramate-related pregnancies.
Women Urged to Consult Specialists Before Stopping Medication
Pregnant women or those planning pregnancy should never stop topiramate without medical advice. Suddenly quitting can trigger more seizures. In 2021, safer alternatives like lamotrigine and levetiracetam were recommended for pregnancy as they don’t carry the same birth defect risks.
New Warning Symbols and Leaflet Updates to Boost Awareness
The CHM also ordered updates to topiramate packaging. Expect a new red circle symbol with a line through a pregnant woman on every box, plus clearer warnings inside the product leaflet about pregnancy risks.
Healthcare pros and patients can report side effects through the Yellow Card scheme to keep safety monitoring robust.
